Your browser doesn't support javascript.
loading
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Hallin, Jill; Engstrom, Lars D; Hargis, Lauren; Calinisan, Andrew; Aranda, Ruth; Briere, David M; Sudhakar, Niranjan; Bowcut, Vickie; Baer, Brian R; Ballard, Joshua A; Burkard, Michael R; Fell, Jay B; Fischer, John P; Vigers, Guy P; Xue, Yaohua; Gatto, Sole; Fernandez-Banet, Julio; Pavlicek, Adam; Velastagui, Karen; Chao, Richard C; Barton, Jeremy; Pierobon, Mariaelena; Baldelli, Elisa; Patricoin, Emanuel F; Cassidy, Douglas P; Marx, Matthew A; Rybkin, Igor I; Johnson, Melissa L; Ou, Sai-Hong Ignatius; Lito, Piro; Papadopoulos, Kyriakos P; Jänne, Pasi A; Olson, Peter; Christensen, James G.
Afiliação
  • Hallin J; Mirati Therapeutics, Inc., San Diego, California.
  • Engstrom LD; Mirati Therapeutics, Inc., San Diego, California.
  • Hargis L; Mirati Therapeutics, Inc., San Diego, California.
  • Calinisan A; Mirati Therapeutics, Inc., San Diego, California.
  • Aranda R; Mirati Therapeutics, Inc., San Diego, California.
  • Briere DM; Mirati Therapeutics, Inc., San Diego, California.
  • Sudhakar N; Mirati Therapeutics, Inc., San Diego, California.
  • Bowcut V; Mirati Therapeutics, Inc., San Diego, California.
  • Baer BR; Array BioPharma Inc., Boulder, Colorado.
  • Ballard JA; Array BioPharma Inc., Boulder, Colorado.
  • Burkard MR; Array BioPharma Inc., Boulder, Colorado.
  • Fell JB; Array BioPharma Inc., Boulder, Colorado.
  • Fischer JP; Array BioPharma Inc., Boulder, Colorado.
  • Vigers GP; Array BioPharma Inc., Boulder, Colorado.
  • Xue Y; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gatto S; Monoceros Biosystems LLC, San Diego, California.
  • Fernandez-Banet J; Monoceros Biosystems LLC, San Diego, California.
  • Pavlicek A; Monoceros Biosystems LLC, San Diego, California.
  • Velastagui K; Mirati Therapeutics, Inc., San Diego, California.
  • Chao RC; Mirati Therapeutics, Inc., San Diego, California.
  • Barton J; Mirati Therapeutics, Inc., San Diego, California.
  • Pierobon M; George Mason University, Manassas, Virginia.
  • Baldelli E; George Mason University, Manassas, Virginia.
  • Patricoin EF; George Mason University, Manassas, Virginia.
  • Cassidy DP; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Marx MA; Mirati Therapeutics, Inc., San Diego, California.
  • Rybkin II; Henry Ford Medical Center, Detroit, Michigan.
  • Johnson ML; Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee.
  • Ou SI; University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, California.
  • Lito P; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Papadopoulos KP; START Center for Cancer Care, San Antonio, Texas.
  • Jänne PA; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Olson P; Mirati Therapeutics, Inc., San Diego, California.
  • Christensen JG; Mirati Therapeutics, Inc., San Diego, California. christensenj@mirati.com.
Cancer Discov ; 10(1): 54-71, 2020 01.
Article em En | MEDLINE | ID: mdl-31658955

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acetonitrilas / Piperazinas / Pirrolidinas / Proteínas Proto-Oncogênicas p21(ras) / Modelos Animais de Doenças / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acetonitrilas / Piperazinas / Pirrolidinas / Proteínas Proto-Oncogênicas p21(ras) / Modelos Animais de Doenças / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article